Therapeutic Control of the Immune System. June, 2004. Corporate Profile & Mission. Private R&D focused Immunology company with proprietary product candidates addressing large markets with unmet needs
Robart’s Research Institute
St. Michael’s Hospital
U. of Toronto
U. of Western Ontario
London Health Sciences Centre
Phase I/Phase IIa
Phase IIb/Phase III
CD200Fc: (Primary indications: autoimmunity & transplantation)
CD200 MAb: (Primary indications: hematological malignancies)
Receptor antagonists (Primary indications: Inflammatory disease & cancer)
Fgl2 MAb: (Primary indication: viral hepatitis)
Major market coverage (US, EP, JP, CA, AU)
(Allelix, YM Biosciences)
Chairman, Ontario Research and Development Fund & Canadian Medical Discoveries Fund
Brian Underdown, Ph.D.
Managing Director, Science and Technology, MDS Capital Corp.
Niclas Stiernholm, Ph.D.
Robert Hall, M.B.A.
Director, Venture Capital Division, Business Development Bank of Canada
Julia Levy, Ph.D.
Founder and Executive Chairman, Scientific Advisory Board, QLT Inc.
Elizabeth Corsi, Pharm D.President & Chief Executive Officer, Eximias Pharmaceutical Corporation
Michael Moore, Ph.D. D.Sc.
Chief Executive Officer, PIramed Ltd.
Gary Levy, M.D.
TTI Founding Scientist RepresentativeBoard of Directors
Director, Multi-Organ Transplant Program at The Toronto Hospital and CIHR Group in Immunology and Transplantation
Director of Research, Immunogenetics and Transplantation, Brigham and Women’s Hospital, Boston
Executive Vice President, University Health Network Global Ventures
Associate Professor of Neurology, Harvard Medical School, Boston
Professor, Head Kennedy Institute of Rheumatology, Imperial College London, UK
Niclas Stiernholm, PhD
Chief Executive Officer
Tel: 416-595-0627 x222
96 Skyway Avenue
Toronto, Ontario, M9W 4Y9
Bob Uger, PhD
Vice President, R&D
Tel: 416-595-0627 x260